Last updated: May 24, 2026
Methotrexate Sodium Suppliers: Who Manufactures It, What Forms Are Sourced, and How to De-Risk Procurement
Methotrexate sodium is a mature, broadly manufactured generic active pharmaceutical ingredient (API) and finished dosage drug. Supplier selection is driven by (1) target strength and dosage form (tablets vs injectable), (2) whether procurement is for API, sterile drug product, or both, and (3) compliance profile for U.S. FDA and global quality systems. A sourcing program should map suppliers to DMF status (API), ANDA/NDA listing (finished product), sterile manufacturing capability, and distribution licensing.
Who supplies methotrexate sodium tablets and injectable drug product in the US market?
US commercial supply: common procurement paths
Most “methotrexate sodium” procurement falls into one of three models:
- ANDA-listed finished drug products (tablets and/or injectable) sourced from manufacturers with FDA approvals and U.S. label authorization.
- API supply for internal formulation from DMF holders or API manufacturers feeding finished dosage licensees.
- Contract sterile manufacturing for methotrexate injectable where sterile fill-finish is outsourced to a sterile CDMO operating under GMP.
Key finished dosage forms that shape supplier universe
- Tablets: methotrexate sodium oral tablets (commonly 2.5 mg).
- Injection: methotrexate sodium sterile injection (single-dose or multi-dose formats vary by label).
What companies supply methotrexate sodium API, and how do you verify their regulatory footprint?
API due diligence checklist
Supplier qualification for methotrexate sodium API should be evidence-based:
- FDA Drug Master File (DMF) status: confirm relevant DMF types (API manufacturing, drug substance).
- Site-specific GMP alignment: API manufacture site(s) and any solvent, crystallization, and drying steps tied to DMF.
- Impurity and specification control: methotrexate impurity profile and over-limit OOS remediation history.
- Shipping and cold chain: typically not required for methotrexate sodium API, but verify packaging integrity and handling.
Sourcing risk hotspots for methotrexate sodium API
- Crystallization and polymorph control (process capability and batch consistency)
- Batch-to-batch impurity variability
- Sterile downstream linkage risk if API is used for injectable drug product (DMF and finished drug product must be aligned)
Which sterile drug product suppliers make methotrexate sodium injection?
Sterile capability requirements
For injectable methotrexate sodium, supplier qualification needs to address:
- Aseptic manufacturing and fill-finish controls
- Container closure system validation
- Sterility assurance level, environmental monitoring, and media fill track record
- Packaging configuration and needle/syringe compatibility if supplied as prefilled units
How to screen injection suppliers fast
- Confirm the supplier has FDA-approved manufacturing and product labeling coverage for methotrexate injection in the target strength format.
- Require evidence of sterile GMP compliance for the actual site producing the finished dosage, not only the corporate umbrella.
How do you choose a methotrexate sodium supplier by strength and dosage form (2.5 mg tablets vs injection)?
Form-specific sourcing approach
- Tablets (oral): prioritize tablet compression and coating lines, blending uniformity controls, and packaging line validation.
- Injection: prioritize aseptic controls and container closure performance, plus sterility and endotoxin specification adherence.
Practical procurement segmentation
Procurement teams should maintain separate supplier scorecards for:
- Tablet manufacturing sites
- Injection sterile sites
- API sites feeding both
What patents matter for methotrexate sodium suppliers, and can supplier choice be constrained by exclusivity?
Patent estate reality for methotrexate sodium
Methotrexate sodium is a legacy small-molecule with extensive generic coverage. In practice, supplier availability is less constrained by active exclusivity and more constrained by:
- regulatory compliance status,
- manufacturing capacity,
- and drug supply chain robustness.
Where patent issues still affect sourcing
Even with mature drugs, patent constraints can still show up as:
- ANDA exclusivity edges tied to specific formulation or process improvements,
- method-of-use coverage that blocks certain label claims, and
- process patents that affect manufacturing changes.
What is the Orange Book status of methotrexate sodium products, and how does that impact suppliers?
Orange Book influence
If the Orange Book lists active patents for a specific methotrexate sodium finished product, then:
- generic competition may be limited to approved Paragraph IV candidates or design-around pathways, and
- supplier availability may cluster around label-compatible products.
Why this matters for procurement
Supplier selection should be tied to the exact FDA label needed (strength, dosage form, route), because “methotrexate sodium” is not a single interchangeable SKU.
When do methotrexate sodium tablets and injectable lose exclusivity?
Typical exclusivity mechanics
For generic-driven products, exclusivity events are usually:
- limited to the first approved generic in a given filing family,
- or tied to specific patent-related exclusivity decisions.
Procurement impact
Even when patents expire, supply continuity depends on manufacturing line readiness, QA release throughput, and packaging availability.
Are there Paragraph IV challenges or ANDA litigation involving methotrexate sodium that affect supply?
Litigation impact on availability
Patent litigation can affect supply via:
- settlement-driven exclusivity periods for certain generic manufacturers,
- “design-around” delays,
- and temporary injunction risk.
How to operationalize litigation intelligence
Track:
- case captions at the district court level,
- settlement dates,
- and which ANDA numbers are involved,
then map those back to:
- the specific NDCs and strengths in your purchasing catalog.
What generic entry risks exist for methotrexate sodium if you add new suppliers?
Entry risk categories
- Regulatory readiness risk: product approval status for the exact NDC.
- Quality release risk: batch disposition delays can cause intermittent shortages.
- Manufacturing transfer risk: API supply chain changes can force requalification.
Supplier onboarding controls
- require recent CoAs and recent batch release lead time history,
- validate packaging and labeling match,
- and confirm stability data that matches your shelf-life program.
How does methotrexate sodium sourcing compare with methotrexate (base) or other salt forms?
Salt form interchangeability
Methotrexate sodium vs other methotrexate forms is not always a plug-and-play switch:
- excipient systems differ by label,
- dissolution characteristics can change,
- injection presentations can vary in pH, buffer, and container closure.
Procurement implication
Supplier choice must match the label requirement in your formulary:
- route (oral vs injection),
- strength,
- dosage form,
- and packaging.
Which countries supply methotrexate sodium and where do supply disruptions typically occur?
Geography
Methotrexate sodium is produced globally across common small-molecule manufacturing hubs. Procurement programs should:
- diversify across API and finished product sites,
- keep contingency plans for site-specific GMP events,
- and maintain safety stock for injection formats.
Disruption patterns that matter
- sterile site contamination events,
- API batch rejection due to impurity controls,
- container closure supply shortages,
- and logistics-driven batch release delays.
How strong is the patent estate for methotrexate sodium, and does it limit licensing or contract manufacturing?
Licensing and contract manufacturing
For mature small molecules, the limiting factor is usually:
- capacity and regulatory approval status,
not active patent barriers.
What still requires legal mapping
If you are licensing a new supplier for injection packaging or a specific manufacturing route, legal mapping should cover:
- process patents tied to manufacturing changes,
- formulation patents if any exist for excipient or stability improvements,
- and any method-of-use claims that affect label scope.
Key Takeaways
- Methotrexate sodium is broadly supplied, with supplier selection dominated by dosage form (tablet vs sterile injection), regulatory approval status, and GMP track record.
- Procurement should separate qualification into API, oral solid dose, and sterile injection lines to avoid hidden risk.
- Orange Book and patent constraints tend to be less about long-term exclusivity and more about label-specific approval and design-around pathways.
- Supplier onboarding should be evidence-driven: NDC label match, recent batch CoAs, sterile manufacturing controls (for injection), DMF alignment (for API), and stable release timelines.
FAQs
- How can I verify methotrexate sodium API supplier DMF alignment for a specific ANDA?
- What sterile manufacturing controls are required for methotrexate sodium injection supplier qualification?
- Do methotrexate sodium tablets have consistent excipients across suppliers under the same strength label?
- What data should be required to onboard a new methotrexate sodium injectable supplier without disrupting supply?
- How do Paragraph IV settlements affect methotrexate sodium availability for specific NDCs?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
- FDA. Drug Master Files (DMFs): Overview and regulations.
